PREDICTIVE DRUG-COMPANION DIAGNOSTIC TEST FOR CANCER THERAPEUTIC RESISTANCE
Desarrollado por: Instituto de Investigación Biomédica de Bellvitge (IDIBELL)
Treatment failure because of anti-angiogenic (AA) cancer resistance
1. New Chemical Entity (NCE) against a new therapeutic target of AA resistance
2. Biomarker for the prediction of treatment response in cancer patients treated with AA therapies
New predictive drug companion biomarker
NCE for Tumors AA-resistant treatment
In Vitro test for diagnosis, prognosis & prediction of response to cancer treatment
This technology can be used for the prediction of response to AA treatment in cancer patients, as a cancer biomarker (diagnostic kit), that allows the selection of subgroups of patients that will benefit the most from our new treatment, as well as this could clearly translate into decreasing the economic burden of cancer treatment costs for the Public Health Systems.
Estado de protección
The biomarker has successfully been validated in animal models and in vitro with tissue and blood samples from patients. For the biomarker kit we are requesting budgets for the design of our initial prototype.
For the NCE we are currently performing HIT confirmation in vitro and in silico
Cooperación que se desea
IDIBELL is seeking a company partner to further develop the technology through a co-development and license agreement.
Responsable: Área de Desarrollo de Negocio e Innovación
Oficina de Transferencia de Tecnología
Contacto (Tel./mail): 93 260 71 06 / Innovacio@idibell.cat
- En desarrollo, Transferible
- Tecnología sanitaria:
- Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...), Medicamentos - Farma